松本 一宏 (マツモト カズヒロ)

Matsumoto, Kazuhiro

写真a

所属(所属キャンパス)

医学部 泌尿器科学教室 (信濃町)

職名

専任講師

経歴 【 表示 / 非表示

  • 2001年05月
    -
    2002年05月

    慶應義塾大学医学部

  • 2002年06月
    -
    2003年05月

    東京都済生会中央病院

  • 2003年06月
    -
    2004年05月

    東京医科大学医学科

  • 2004年06月
    -
    2007年04月

    大田原赤十字病院

  • 2005年05月
    -
    2006年05月

    慶應義塾大学医学部

全件表示 >>

学歴 【 表示 / 非表示

  • 1995年04月
    -
    2001年03月

    慶應義塾大学, 医学部

    大学, 卒業

学位 【 表示 / 非表示

  • 博士(医学), 慶應義塾大学, 論文, 2019年03月

    根治的前立腺全摘除術後の適切なフォロー アップスケジュールの確立

免許・資格 【 表示 / 非表示

  • 医師免許, 2001年05月

  • 日本泌尿器科学会専門医, 2006年04月

  • 日本癌治療認定医機構認定医, 2011年04月

  • 日本泌尿器科学会指導医, 2011年04月

  • 泌尿器腹腔鏡技術認定医, 2012年04月

全件表示 >>

 

研究キーワード 【 表示 / 非表示

  • 前立腺がん

  • 尿路上皮がん

  • 後腹膜軟部腫瘍

 

論文 【 表示 / 非表示

  • Three-dimensional single-cell imaging for the analysis of RNA and protein expression in intact tumour biopsies

    Tanaka N., Kanatani S., Kaczynska D., Fukumoto K., Louhivuori L., Mizutani T., Kopper O., Kronqvist P., Robertson S., Lindh C., Kis L., Pronk R., Niwa N., Matsumoto K., Oya M., Miyakawa A., Falk A., Hartman J., Sahlgren C., Clevers H., Uhlén P.

    Nature Biomedical Engineering (Nature Biomedical Engineering)  4 ( 9 ) 875 - 888 2020年09月

     概要を見る

    © 2020, The Author(s), under exclusive licence to Springer Nature Limited. Microscopy analysis of tumour samples is commonly performed on fixed, thinly sectioned and protein-labelled tissues. However, these examinations do not reveal the intricate three-dimensional structures of tumours, nor enable the detection of aberrant transcripts. Here, we report a method, which we name DIIFCO (for diagnosing in situ immunofluorescence-labelled cleared oncosamples), for the multimodal volumetric imaging of RNAs and proteins in intact tumour volumes and organoids. We used DIIFCO to spatially profile the expression of diverse coding RNAs and non-coding RNAs at the single-cell resolution in a variety of cancer tissues. Quantitative single-cell analysis revealed spatial niches of cancer stem-like cells, and showed that the niches were present at a higher density in triple-negative breast cancer tissue. The improved molecular phenotyping and histopathological diagnosis of cancers may lead to new insights into the biology of tumours of patients.

  • Umbilical closure using 2-octyl cyanoacrylate in transumbilical laparoscopic adrenalectomy: A randomized controlled trial

    Fukumoto K., Miyajima A., Matsumoto K., Kobayashi H., Niwa N., Hongo H., Kurihara I., Kikuchi E., Oya M.

    International Journal of Urology (International Journal of Urology)  27 ( 8 ) 670 - 675 2020年08月

    ISSN  09198172

     概要を見る

    © 2020 The Japanese Urological Association Objectives: To evaluate postoperative pain and esthetic outcomes in patients undergoing transumbilical laparoscopic adrenalectomy with wound closure using 2-octyl cyanoacrylate. Methods: A total of 26 patients who underwent laparoscopic adrenalectomy with the transumbilical approach and agreed to participate in this study were included. Patients were randomly divided into two groups: the 2-octyl cyanoacrylate group (Glue group) or the non-use group (non-Glue group). A single surgeon (AM) carried out all procedures between 2014 and 2017. Results: There were no significant differences in the clinical background of the Glue and non-Glue groups. The number of patients with moderate or high levels of pain in the resting/moving period on postoperative days 1, 2 and 3 was 6/10 (46%/77%), 6/9 (46%/69%) and 3/5 (23%/38%) in the non-Glue group, and 5/7 (38%/54%), 2/7 (15%/54%) and 1/3 (8%/23%) in the Glue group. These differences were not significant. In the subgroup analysis of patients aged <50 years, the numbers were 4/6 (57%/86%), 5/7 (71%/100%) and 3/5 (43%/71%) in the non-Glue group, and 3/4 (33%/44%), 1/4 (11%/44%) and 0/1 (0%/11%) in the Glue group in the resting/moving period. On postoperative days 2 and 3, these differences were significant (P = 0.035 and 0.037 in the resting period, and P = 0.017 and 0.013 in the moving period). Conclusions: 2-octyl cyanoacrylate can be used safely for laparoscopic adrenalectomy with the transumbilical approach, and might be useful for reducing postoperative pain in patients aged <50 years.

  • External validation of the "optimal PSA follow-up schedule after radical prostatectomy” in a new cohort

    Yanai Y., Matsumoto K., Kosaka T., Takeda T., Tanaka N., Morita S., Mizuno R., Shinojima T., Asanuma H., Oya M.

    International Journal of Clinical Oncology (International Journal of Clinical Oncology)  25 ( 7 ) 1393 - 1397 2020年07月

    ISSN  13419625

     概要を見る

    © 2020, Japan Society of Clinical Oncology. Background: Biochemical recurrence (BCR) after radical prostatectomy (RP) is most commonly diagnosed by detecting an increase in asymptomatic prostate-specific antigen (PSA). We previously reported the “optimal PSA follow-up schedule after RP”. The aim of this study was to confirm the usefulness and safety of that follow-up schedule in another cohort. Methods: We retrospectively reviewed the clinicopathological data of 798 consecutive patients who underwent radical prostatectomy between 2009 and 2017. We examined all PSA values measured during follow-up. Furthermore, we estimated the PSA value when we observed the “optimal PSA follow-up schedule” at each timing in the virtual follow-up. BCR was defined as an elevation of PSA to greater than 0.2 ng/ml, and the ideal PSA range for detection of BCR was regarded to be 0.2–0.4 ng/ml. Results: During the mean follow-up period of 5.8 years, BCR occurred in 115 (14.9%) patients and the frequency of virtual follow-up was significantly lower than the actual frequency. However, overlooking of BCR (detecting BCR when PSA exceeded 0.4 ng/ml) was observed in 17 patients, which is higher than the actual frequency of overlooking (12 patients). Therefore, we modified the follow-up schedule, which could achieve the lower follow-up frequency and a limited number of overlooking of BCR (7 patients). Conclusion: This external validation study revealed that the "modified optimal PSA follow-up schedule after RP" can reduce the frequency of PSA measurement with a limited risk of overlooking BCR.

  • Type of patients in whom biochemical recurrence after radical prostatectomy can be observed without salvage therapy

    Matsumoto K., Niwa N., Hagiwara M., Kosaka T., Tanaka N., Takeda T., Morita S., Mizuno R., Shinojima T., Hara S., Asanuma H., Oya M.

    World Journal of Urology (World Journal of Urology)  38 ( 7 ) 1749 - 1756 2020年07月

    ISSN  07244983

     概要を見る

    © 2019, Springer-Verlag GmbH Germany, part of Springer Nature. Purpose: To examine the prognosis after BCR with and without salvage therapy, including radiation and/or androgen deprivation. Methods: The study population consisted of 431 patients, all of whom underwent radical prostatectomy and developed BCR (PSA > 0.2 ng/mL). According to the two risk factors [Gleason score ≥ 8 and PSA-doubling time (DT) < 6 months], we divided the patients into two groups. The high/intermediate-risk group consisted of patients with both or one risk factor. On the other hand, patients with neither factor were in the low-risk group. We set the starting point at the timing of BCR, and the endpoints were development to castration-resistant prostate cancer (CRPC) and cancer-specific death. Results: During the mean follow-up period of 8.3 years after BCR, CRPC was observed in 49 patients (11.4%), and 21 patients (4.9%) died due to prostate cancer. We first divided the 191 high/intermediate-risk patients according to the PSA level (PSA < 1.0 ng/mL, PSA 1.0–4.0, and PSA > 4.0 or no therapy) at the initiation of salvage therapy, including radiation and/or androgen deprivation. We found that delayed (PSA > 4.0 ng/mL) or no salvage therapy was significantly associated with CRPC and cancer-specific death. In the 240 low-risk patients, Kaplan–Meier curves demonstrated no significant difference in CRPC-free survival or cancer-specific survival within 10 years from the timing of BCR. Conclusions: Observation after BCR without salvage therapy or delayed administration may be an option for low-risk patients with a Gleason score ≤ 7 and PSA-DT ≥ 6 months when their life expectancy is within 10 years.

  • Appropriate timing for a biochemical evaluation after adrenalectomy for unilateral aldosterone-producing adenoma

    Takamatsu K., Takeda T., Hattori S., Tanaka N., Morita S., Matsumoto K., Kosaka T., Mizuno R., Shinojima T., Kikuchi E., Asanuma H., Kurihara I., Itoh H., Oya M.

    Clinical Endocrinology (Clinical Endocrinology)  92 ( 6 ) 503 - 508 2020年06月

    ISSN  03000664

     概要を見る

    © 2020 John Wiley & Sons Ltd Context: The oversecretion of plasma aldosterone by unilateral aldosterone-producing adenoma (APA) can be cured by adrenalectomy. However, the time needed for the endocrine environment to normalize remains unclear. Objective: To clarify adequate timing for a biochemical evaluation in unilateral APA patients after adrenalectomy. Design and patients: A total of 166 unilateral APA patients were retrospectively reviewed. We evaluated the plasma aldosterone concentration (PAC) (pg/mL), active renin concentration (ARC) (pg/mL), aldosterone-renin ratio (ARR; PAC/ARC), serum potassium concentration and estimated glomerular filtration rate (eGFR) at 1, 3 and 6 postoperation months (POM). Results: PAC was significantly lower at 1POM than at presurgery (presurgery; 407.2, 1 POM; 90.0 pg/mL, P <.001). ARC did not increase from baseline at 1POM, but significantly increased at 3POM (presurgery; 4.43, 1POM; 4.87, 3POM; 11.3 pg/mL, P <.001). ARR significantly decreased at 1POM (presurgery; 146.9, 1 POM; 26.3, P <.001) although ARC did not increase at 1POM. Among the 34 patients who had hypokalaemia presurgery, it was resolved in 28 (82%) at 1POM and in all (100%) at 3POM. The biochemical outcomes at 1POM were 131 (79%) complete, 20 (12%) partial and 15 (9%) absent successes, while at 3POM, 147 (89%) were complete, 9 (5%) partial and 10 (6%) absent. Twenty-three (14%) patients were reclassified into different biochemical outcomes between 1 and 3POM, whereas only 5 (3%) changed between 3 and 6POM. Conclusion: The appropriate timing for a biochemical evaluation of unilateral APA patients treated with laparoscopic adrenalectomy appears to be 3 months or more after surgery.

全件表示 >>

KOARA(リポジトリ)収録論文等 【 表示 / 非表示

全件表示 >>

研究発表 【 表示 / 非表示

  • 高齢者の表在性膀胱癌間じゃに対するBCG膀注の再発予防効果についての検討

    弓削和之、菊地栄次、松本一宏、宮嶋 哲、中川 健、大東貴志、中島 淳、大家基嗣

    第96回日本泌尿器科学会総会 (横浜) , 

    2008年04月

    口頭発表(一般)

  • 放射線照射後の膀胱穿孔に伴う急性腎不全の一例

    伊藤祐二郎、松本一宏、金子 剛、井手広樹、水野隆一、大東貴志、村井 勝

    日本泌尿器科学会東京地方会 (第582回) , 

    2006年06月

    口頭発表(一般)

競争的研究費の研究課題 【 表示 / 非表示

  • 酸化ストレス応答に着目した間質性膀胱炎の発症メカニズム解明と治療法の開発

    2021年04月
    -
    2024年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 松本 一宏, 基盤研究(C), 補助金,  研究代表者

  • ドラッグ・リポジショニングを用いた、膀胱癌に対する抗癌剤注入療法の効果増強

    2018年09月
    -
    2019年08月

    第一三共奨学寄付プログラム, 未設定

  • ドラッグ・リポジショニングを用いた、筋層非浸潤性膀胱癌の抗癌剤注入療法耐性の克服

    2018年08月
    -
    2019年07月

    サノフィ・ジャパングループ教育研究助成, 未設定

  • ドラッグ・リポジショニングを用いた、筋層非浸潤性膀胱癌に対する新規膀胱内注入療法の開発

    2018年05月
    -
    2019年04月

    慶應義塾大学学事振興資金, 未設定

  • ドラッグ・リポジショニングを用いた、膀胱癌に対する新規膀胱内注入療法

    2018年04月
    -
    2021年03月

    文部科学省・日本学術振興会, 文部科学省科学研究費補助金(基盤研究C), 松本 一宏, 補助金,  研究代表者

全件表示 >>

受賞 【 表示 / 非表示

  • 慶應義塾大学医学部三四会奨励賞

    2015年06月

  • IJU Reviewers of the Year 2013

    2014年04月

  • 第49回癌治療学会優秀演題賞

    2011年11月

  • 第45回癌治療学会優秀演題賞

    2007年10月

 

担当授業科目 【 表示 / 非表示

  • 泌尿器科学講義

    2023年度

  • 泌尿器科学講義

    2022年度

  • 泌尿器科学講義

    2021年度

  • 泌尿器科学講義

    2020年度

  • 泌尿器科学講義

    2019年度